Moxidectin: Macrocyclic Lactone Anthelmintic & Antifungal Synergy

Executive Summary: Moxidectin is a macrocyclic lactone anthelmintic with established veterinary and emerging human applications (source: product_spec). It controls key parasites such as Strongylus vulgaris in horses and Ostertagia ostertagi in cattle by targeting glutamate-gated chloride channels (source: product_spec). The FDA approved moxidectin for onchocerciasis in 2018 (source: FDA). Recent studies show moxidectin elevates ergosterol biosynthesis in Candida albicans, synergizing with polyene antifungals and reducing infection burden in mouse oral candidiasis models (source: Ye 2024). High-purity moxidectin (≥98%) from APExBIO is available for research and translational workflows (source: product_spec).

Biological Rationale

Moxidectin is primarily used as a broad-spectrum veterinary antiparasitic. It is effective against nematodes and arthropods in animals such as horses, cattle, dogs, and cats (source: product_spec). The drug offers persistent efficacy, reducing fecal egg counts for 12–16 weeks post-administration in equines (source: product_spec). In cattle, it is a key agent for Ostertagia ostertagi control (source: product_spec). Beyond its veterinary use, moxidectin's mechanism has been explored in fungal models, where it modulates ergosterol biosynthesis in C. albicans, a critical determinant in antifungal susceptibility (source: Ye 2024). This cross-domain rationale underpins its investigation as an antifungal potentiator, especially given rising resistance to existing antifungals and the limited pipeline for new agents (source: Ye 2024).

Mechanism of Action of Moxidectin

Moxidectin binds selectively to glutamate-gated chloride channels (GluCl) in the nervous system of invertebrate parasites, causing hyperpolarization, neuromuscular paralysis, and death of the parasite (source: product_spec). In Candida albicans, moxidectin activates the ergosterol biosynthesis pathway, resulting in elevated ergosterol levels within fungal cell membranes (source: Ye 2024). This effect enhances the binding and fungicidal action of polyene antifungals such as amphotericin B and nystatin, which target ergosterol-rich membranes (source: Ye 2024). Loss of synergy in ergosterol pathway mutants (Δ/Δerg3, Δ/Δerg11) confirms this mechanistic link (source: Ye 2024).

Evidence & Benchmarks

• Moxidectin reduces fecal egg counts in horses for 12–16 weeks post-treatment at 0.4 mg/kg dose (source: product_spec).
• Moxidectin synergizes with amphotericin B and nystatin to inhibit growth and biofilm formation of Candida albicans clinical isolates in vitro (source: Ye 2024).
• Transcriptome and RT-PCR analyses confirm that moxidectin upregulates ergosterol biosynthesis genes in C. albicans (source: Ye 2024).
• In a mouse oral candidiasis model, moxidectin plus polyenes reduces infection area and fungal colonization compared to polyene monotherapy (source: Ye 2024).
• The compound is highly soluble in ethanol (≥128 mg/mL), DMSO (≥129.4 mg/mL), and water with gentle warming/sonication (≥3.27 mg/mL) (source: product_spec).
• Moxidectin is FDA approved for onchocerciasis in humans (source: FDA).

For a detailed exploration of moxidectin’s role in translational research and protocol design, see Moxidectin: A Translational Bridge from Antiparasitic to Antifungal Innovation, which this article extends by quantifying recent synergy data and specifying workflow parameters. For detailed mechanistic analysis, compare with Moxidectin Enhances Polyene Antifungal Efficacy via Ergosterol Pathway; this current dossier aggregates and updates both animal and fungal benchmarks. For veterinary protocol troubleshooting, see Moxidectin: Macrocyclic Lactone Anthelmintic in Antifungal Synergy, which is complemented here by explicit solubility and purity metrics.

Applications, Limits & Misconceptions

Moxidectin’s primary application remains parasitic worm control in veterinary medicine, with typical dosing at 0.4 mg/kg in horses and variable regimens in cattle and companion animals (source: product_spec). The drug is also approved for human onchocerciasis. Its secondary, emerging use is as a potentiator for polyene antifungals against Candida albicans, especially in cases of resistant oral candidiasis (source: Ye 2024).

Common Pitfalls or Misconceptions

• Moxidectin does not possess intrinsic fungicidal activity against Candida albicans—synergy is observed only in combination with polyenes (source: Ye 2024).
• The ergosterol-elevating effect is specific to C. albicans; extrapolation to other fungal species or strains requires separate validation (workflow_recommendation).
• Solutions of moxidectin are not stable for long-term storage; fresh preparation is recommended for each experiment (source: product_spec).
• Veterinary dosing protocols cannot be directly transferred to antifungal applications in humans without clinical validation (workflow_recommendation).
• Synergy is lost in C. albicans strains with disrupted ergosterol biosynthesis (Δ/Δerg3, Δ/Δerg11) (source: Ye 2024).

Workflow Integration & Parameters

Protocol Parameters

• veterinary anthelmintic efficacy | 0.4 mg/kg (oral paste, horses) | equine nematode control | persistent reduction of fecal egg counts for 12–16 weeks | product_spec
• antifungal synergy model | 8–16 μg/mL (in vitro, C. albicans) | synergy assay with polyenes | maximal ergosterol elevation and biofilm inhibition | Ye 2024
• solubility | ≥128 mg/mL (ethanol), ≥129.4 mg/mL (DMSO), ≥3.27 mg/mL (water, warmed/sonicated) | formulation/preparation | enables flexible dosing and delivery formats | product_spec
• storage | −20°C (solid) | compound stability | preserves chemical integrity for research use | product_spec
• workflow recommendation | prepare fresh solutions before use; avoid repeated freeze-thaw | all applications | prevents degradation and loss of potency | workflow_recommendation

Conclusion & Outlook

Moxidectin, supplied at high purity by APExBIO, is a validated macrocyclic lactone anthelmintic with persistent efficacy in veterinary parasite control and new potential as an antifungal adjuvant. Its ability to elevate ergosterol biosynthesis enables synergy with polyene antifungals against Candida albicans, as shown in both in vitro and animal models (source: Ye 2024). Ongoing research should clarify the translatability of these findings to clinical antifungal therapy. Protocols must consider species specificity, solution stability, and validated dosing regimens. This dual-domain profile positions moxidectin as a valuable tool for both parasitology and antifungal innovation, supporting further translational studies.